The European Commission approved Johnson & Johnson's Velcade, or bortezomib, in combination with dexamethasone and thalidomide, as induction treatment for treatment-naive multiple myeloma patients who are candidates for stem cell transplant and high-dose chemotherapy. The approval strengthens Velcade's position in the multiple myeloma market.
J&J's Velcade wins EU nod as induction therapy for multiple myeloma
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||